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ABSTRACT
The treatment of psychiatric disorders presents threemajor challenges
to the research and clinical community: defining a genotype associated
with a disorder, characterizing themolecular pathologyof eachdisorder
anddevelopingnew therapies.ThisReviewaddresseshowcellularand
animal systems can help to meet these challenges, with an emphasis
on the role of the zebrafish. Genetic changes account for a large
proportion of psychiatric disorders and, as gene variants that
predispose to psychiatric disease are beginning to be identified in
patients, these are tractable for study in cellular and animal systems.
Defining cellular and molecular criteria associated with each disorder
will help to uncover causal physiological changes in patients and will
lead to more objective diagnostic criteria. These criteria should also
define co-morbid pathologies within the nervous system or in other
organ systems. The definition of genotypes and of any associated
pathophysiology is integral to the development of new therapies.
Cell culture-based approaches can address these challenges by
identifying cellular pathology and by high-throughput screening of gene
variants and potential therapeutics. Whole-animal systems can define
the broadest function of disorder-associated gene variants and the
organismal impact of candidate medications. Given its evolutionary
conservation with humans and its experimental tractability, the
zebrafish offers several advantages to psychiatric disorder research.
These include assays ranging from molecular to behavioural, and
capability for chemical screening. There is optimism that the multiple
approaches discussed here will link together effectively to provide new
diagnostics and treatments for psychiatric patients.
KEY WORDS: Zebrafish, Psychiatric disorders, Animal models,
Co-morbidities, Chemical screens, Autism, Schizophrenia
Introduction
Accounting for nearly a quarter of global disability, psychiatric
disorders represent a pervasive societal challenge (Whiteford et al.,
2013), making the need to precisely diagnose and treat these disorders
urgent. Psychiatry faces special challenges compared with other
branches of medicine. Whereas twin and family studies have clearly
demonstrated that psychiatric disorders are heritable, recent data reveal
that the genetics of psychiatry are very complex (Kendler, 2013). A
first major challenge for psychiatry, then, is to link molecular and
cellular alterations to changes at the genome level – the ‘genotype’.
Hundreds of loci in the human genome have been implicated in major
psychiatric disorders, such as autism spectrum disorder, bipolar
disorder and schizophrenia (Koboldt et al., 2013; Schreiber et al.,
2013). Moreover, many of these loci are shared between different
psychiatric disorders (Cross-Disorder Group of the Psychiatric
Genomics Consortium and Genetic Risk Outcome of Psychosis
Consortium, 2013), suggesting commonalities in dysfunction. These
generally polygenic disorders are thought to arise from an array of
gene variants that each contribute incrementally to disease risk
(Gratten et al., 2014). For example, a genome-wide association study
for schizophrenia estimates that around8300 variants account for 32%
of the heritability of schizophrenia (Ripke et al., 2013).With this high
number of possible risk genes, determining whether gene variants are
causally linked to a particular disorder remains difficult. A portion of
autism spectrum disorder patients can be accounted for by various
genetic syndromes tightly associated with known mutations and
cytological anomalies (Caglayan, 2010). However, even in these
Mendelian disorders, there is incomplete penetrance of autism and
variable phenotypic presentations; for example, although fragile X
syndrome is considered a syndromic form of autism, only around 30%
of fragile X syndrome patients (who carry mutations in the FMR1
gene) are diagnosed with autism (Fatemi and Folsom, 2011). This
incomplete penetrance indicates that even when one predominant
gene is associated with a disorder, other regions of the genome and/or
the environment can modify its severity. Uncovering the complex
genetics underlying psychiatric disorders and linking genotype to
phenotype therefore remains a huge challenge.
A secondmajor challenge for psychiatry is to improve diagnostics
by defining the molecular, cellular and biochemical changes
associated with each disorder – its ‘molecular pathology’. The
behavioural criteria currently used to diagnose these disorders are
powerful, but also complex, qualitative and sometimes subjective,
in which independent tests of the same patient might not yield the
same diagnosis (Lord et al., 2012). Molecular pathology of a
disorder might include changes in gene expression, as well as
changes in cell biology – including neuronal, glial or synaptic cell
biology – defining biomarkers that are putatively causal to the
disorder. The more closely associated the changes are to the key
affected cells, the more robust the definition of molecular pathology.
More distantly associated biomarkers, such as hormone levels in
blood or urine, are also useful because they are easier to measure.
One complication that is encountered when defining molecular
pathology is the presence of co-morbid, or co-occurring, disorders and
symptoms, which might contribute to the overall pathology of a
disorder (Kanner, 2013; Muir-Cochrane, 2006). For example, nearly
50% of peoplewith a psychiatric diagnosis meet the criteria for two or
more distinct psychiatric disorders (Kessler et al., 2005b). The genetic
underpinnings of psychiatric and non-neural co-morbid symptoms are
presumed to be linked, although this relationship has not been
thoroughly addressed. Whereas some co-morbid symptoms impact
the central nervous system (CNS), they can also affect other organs,
leading to intestinal or immune dysfunction, obesity, hypotonia and
cardiovascular disease (Hamdani et al., 2013; Kohane et al., 2012).
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Interestingly, individuals with disorders as behaviourally diverse as
autism spectrum disorders (ASDs) and schizophrenia appear to share
certain non-CNS symptoms, although it is not known whether a
common molecular basis underlies this overlap.
Defining the molecular pathologies that underpin these disorders
will allow for more precise diagnostics to be developed, and might
establish subgroups of a disorder consistently linked to a specific
biomarker. Another crucial outcome of defining the molecular
changes that associate with psychiatric disorders is that these will
help to identify new therapeutic targets.
Many current psychiatric medications were serendipitously
discovered over 50 years ago. The targets of these drugs are
unknown or not fully understood, and these medications are still
used, despite significant side effects, often because there is no better
alternative (Hyman, 2014). Therefore, a third major challenge for
psychiatry is to identify new therapeutics. Although psychiatric
medications account for the largest revenue in the pharmaceutical
industry (Hyman, 2012), the funding and enthusiasm for psychiatric
drug development is dwindling. A profit incentive is not enough to
overcome the enormous cost of clinical trials and the high rates of
failure. Although there is hope that patients, and therefore therapies,
would fall into a limited number of categories, personalized
approaches might be necessary because the genetics of psychiatric
disorders is so complex. This possibility extends the challenge of
therapeutic development in that genotype and phenotype will have
to be linked on a per-patient basis.
In overcoming these three major challenges, it is important to
determine which experimental tools would most effectively
address them. There is no direct route from diagnosis to a new
therapeutic without intervening experimental analysis (Fig. 1).
Based on successful approaches used in a collaborative and
iterative fashion in other disorders such as cancer (Rudrapatna
et al., 2012; White et al., 2013), in which the molecular details are
better understood, multiple approaches will be essential to improve
the diagnostics and treatments for psychiatric disorders. Together
with clinical input, useful approaches include sequencing and
bioinformatics analysis, -omic approaches such as proteomics and
metabolomics, cell culture assays and whole-animal assays. We
focus the remainder of this Review on a few pivotal cellular and
whole-animal approaches to address these three major challenges
of psychiatric disorders (attributes summarized in Table 1),
including neuronal and cell culture, induced pluripotent stem cell
culture, cerebral organoids, C. elegans, Drosophila and mice. We
conclude with an emphasis on the zebrafish, a laboratory organism
with tools and attributes to study a wide range of psychiatrically
relevant genetics and pathology, and a key vertebrate for chemical
screens.
Cellular tools for psychiatric disorder research
Cell cultures, ranging from immortalized cell lines to patient-
derived induced pluripotent stem cells (iPSCs), offer researchers
and clinicians a high-throughput manner in which to study cellular
pathology associated with psychiatric disorders. This approach is
also invaluable for screening large chemical compound libraries for
potential therapeutics that can reverse these cellular pathologies. In
the case of iPSCs, patient-specific genetic variation is replicated for
comprehensive study of genetic effects on cellular pathology.
Furthermore, iPSCs can be differentiated to form three-dimensional
organoids resembling rudimentary forms of organs, to facilitate the
study of whole organ pathology in vitro (Box 1).
Cell culture approaches
Both non-neuronal and neuronal cell culture are useful for
elucidating the genetic basis of a disorder and for assessing the
pharmacologic effects of potential therapies at the cellular level. For
instance, the toxicity, receptor binding and dopamine transport-
inhibition properties of Ritalin have been measured in human and
hamster cells, as well as the expression levels of the dopamine
transporter gene variants associated with attention deficit
hyperactivity disorder (ADHD) (Grünblatt et al., 2013). At the
level of neural circuits, the development of mammalian cortico-
striatal cultures has facilitated analysis of synaptic activity. By
mixing dissociated mouse neurons from cortex and striatum,
synaptic connections that form can be studied and manipulated
genetically or pharmacologically (Randall et al., 2011).
The development of iPSCs derived from patient biopsy, usually
of the skin, has offered a unique system to study cellular pathology
related to psychiatric disorders. When differentiated into neurons,
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Fig. 1. Research strategy and integrative approach for overcoming the
three major challenges of psychiatry. For psychiatric disorders, there is no
direct path from diagnosis to treatment. Three major challenges (purple) must
be overcome by the use of different assays (orange). (1) First is the challenge
of correct genotype identification, which can be determined by sequencing and
bioinformatics methods, and using cell culture and animal systems to study
disease-associated gene variants (blue arrows). Patient-associated
genotypes can also be used to generate cell culture and animal tools.
(2) The use of -omic approaches (such as metabolomics, proteomics and
transcriptomics), cell culture and animal systems can provide clues about
pathology (grey arrows). Determining the molecular pathology can improve
diagnostics. (3) Cell culture and animal models can be used in chemical
screens to identify candidate drugs (green arrows). Overall, this illustration
demonstrates that in psychiatry the route from genotype identification to the
understanding of molecular pathology to treatment is not direct but varied and
complex, with cellular and animal models playing an important role.
Box 1. Cell culture approaches
Cell-based approaches:
• Challenges addressed: Genetic interactions and variant analysis,
cell-autonomous phenotypes for biomarkers, therapeutic
development for cellular phenotypes.
• Pros: Patient-specific genetic information, large scale, short time
frame.
• Cons: No behavioural assays, no co-morbidity analysis, no system-
wide or whole-organism screening.
Organoid approaches:
• Challenges addressed: variant analysis, organ-like phenotypes for
biomarkers, therapeutic development.
• Pros: Patient-specific genetic information, three-dimensional (3D)
structure.
• Cons: Immature or partial organs only; no ability for co-morbidity
analysis, no systems/whole-organism toxicity screen.
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iPSCs offer a way to study human cellular phenotypes, and can even
form simple circuits in culture (Shi et al., 2012), in the context of the
patient’s genetic background. iPSCs have revealed clues about
pathology and potential treatments: for example, iPSC-derived
neurons from Rett syndrome patients show reduced synaptic puncta
and decreased glutamatergic signalling, deficits rescued by insulin-
like growth factor 1 (IGF1) application (Marchetto et al., 2010).
IGF1 treatment has shown preliminary signs of ameliorating some
breathing and behavioural abnormalities in patients (Khwaja et al.,
2014). A screen of 1000 compounds using human iPSC-derived
neural progenitor cells identified five compounds that could
increase the proliferation or viability of these cells, hinting at their
potential therapeutic use for modulating neuronal stem cells
(McLaren et al., 2013), an approach that could prove useful for
psychiatric disorders associated with dysregulated neurogenesis,
including autism, schizophrenia, bipolar disorder and depression
(Dodd et al., 2013; Wei et al., 2014). Cell culture and iPSC-derived
neurons can also be used for high-throughput analyses; however,
their application is limited to cellular phenotypes. In addition, iPSC-
derived neurons do not progress developmentally beyond foetal-
type stages (Brennand et al., 2014).
Cell culture approaches: organoids
One surprising finding over the past few years is that stem cells can
organize themselves in vitro into mini organs (Li et al., 2014).
Recently, specialized cultures of iPSCs have generated cerebral
organoids, mini-embryonic brain-like structures (Lancaster and
Knoblich, 2014), with implications for addressing psychiatric
disorders (Box 1). Cerebral organoids derived from a microcephalic
patient with a mutation in cyclin-dependent kinase 5 regulatory
subunit associated protein 2 (CDK5RAP2) were smaller than those
derived from control iPSCs (Lancaster et al., 2013). Mouse models
carrying mutations in the same gene do not show microcephaly,
demonstrating the importance of using human tissue in this analysis.
Studying organoids allows for the discovery and characterization of
phenotypes that might not develop in two-dimensional cell cultures.
Organs presenting co-morbid phenotypes or susceptibility to drug
toxicity, such as the intestine and liver, can also be cultured as
organoids (Spence et al., 2011; Takebe et al., 2013). At present,
cerebral organoids are highly variable in phenotype and do not
recapitulate the precise organization of the brain; however, the
promise of this system is considerable. In the longer term, this
approach might reveal several aspects of a disorder phenotype in a
patient-specific genetic context and support the exploration of drug
treatments (Ranga et al., 2014). Another significant limitation of the
organoid culture is that the whole-animal phenotype is not
recapitulated. We discuss this and other advantages of animal-based
systems below.
Whole-animal tools for psychiatric disorder research
Non-human animal systems are crucial for understanding
phenotypes associated with a specific psychiatric disorder,
allowing phenotypes to be investigated in the whole animal
throughout its life. As human behaviours are often not faithfully
modelled in animal systems (Nestler and Hyman, 2010; O’Leary
and Cryan, 2013), whole-animal analyses might be most useful
when they focus on specific molecular and cellular pathways that
underlie a pathology. The concept of an animal ‘tool’, a biological
system that can provide insight into a disorder without obviously
recapitulating all associated phenotypes, is useful for pre-clinical
studies (Sive, 2011). Numerous whole-animal systems have been
used for analysing aspects of psychiatric disorders, including
invertebrates, such as C. elegans and Drosophila, and vertebrates,
such as zebrafish and mouse. To maximize the utility of different
animals, one must consider the attributes and limitations of each
(Box 2).
Whole-animal approaches: invertebrates
Invertebrate models are cheap to maintain and have short life cycles,
making them useful for rapid, large-scale analysis. For example, the
nematode C. elegans is amenable to RNA interference (RNAi)
screens, and has been used to identify targets of clozapine, one of
Table 1. Cellular systems and animal tools have different attributes
Human
iPSCs
Human cerebral
organoids
Mouse neuronal
cultures C. elegans Drosophila Zebrafish Mouse
Conservation with human
Gene conservation n/a n/a +++ + + ++ +++
Signalling pathways,
neuronal subtypes, circuits
++ +++ ++ + + ++ ++
Brain development, anatomy – + – – – ++ +++
Rapid tests for risk gene function
Variant assays +++ + +++ + + +++ +
Genetic interactions +++ + +++ +++ +++ +++ +
Rapid, transient assays +++ + +++ +++ ++ +++ –
Genome editing +++ +++ +++ ++ ++ +++ +++
Cellular assays in living animal
Neuron structure/sub-types – – – ++ ++ +++ +++
Circuit activity – – – + ++ +++ ++
Transparent embryos – – – +++ – +++ –
Complex whole-animal assays
Behavioural – – – + ++ ++ +++
Digestive, immune, epilepsy – – – + ++ +++ +++
Therapeutic development
Range of whole-animal assays – – – ++ +++ +++ ++
Scale of chemical screens +++ + +++ +++ +++ +++ +
Each attribute is important for understanding psychiatric disorders. There is often a trade-off between themetrics of conservation versus technical ability for these
systems. Zebrafish represent a balance between both. n/a, not applicable; –, not relevant or possible; +, applicable; ++, moderately applicable; +++, highly
applicable. iPSCs, induced pluripotent stem cells. References: McCammon and Sive (unpublished data); (Flinn et al., 2008; Lieschke and Currie, 2007; Wheeler
and Brändli, 2009).
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the most effective drugs for treatment-resistant schizophrenia
(McEvoy et al., 2006). Of 6656 genes analysed in triplicate, 40
candidate suppressors of clozapine-induced phenotypes were
identified, including one targeting the ACR-7 subunit of a
nicotinic acetylcholine receptor (nAChR), homologous to several
human α-like nAChRs (Saur et al., 2013).
Invertebrate genes exhibit some evolutionary conservation with
human genes. Homologues of ∼50% of human disease genes can be
identified in C. elegans (Culetto and Sattelle, 2000). The fruit fly
Drosophila melanogaster has identifiable homologues for 75% of
human genes implicated in disease (Reiter et al., 2001). The FMR1
gene that is mutated in fragile X, the leading cause of inherited
intellectual disability, has a homologue in fruit flies. Drosophila fmr1
mutants challenged the long-held dogma that neurodevelopmental
disorders could not be treated because the aberrant circuitry that leads
to behavioural dysfunction is set duringdevelopment (Leblond, 1964).
However, McBride and colleagues used metabotropic glutamate
receptor (mGluR) antagonists to ameliorate behavioural deficits in a
Drosophila fmr1 mutant; these treatments worked well, whether
administrated to embryos or adults (McBride et al., 2005). Although
these results were replicated in Fmr1mutant mice (Dolen et al., 2007;
Yan et al., 2005), clinical trials for mGluR antagonists failed to
demonstrate sufficient efficacy for some behavioural parameters in
human fragile X patients (Jacquemont et al., 2011). Whether this
failure was due to a lack of translation of the data from invertebrates to
humans or some design flaw in the clinical trials remains unknown.
Despite caveats, invertebrates remain the highest-throughput
organisms for which whole-animal phenotypes can be assessed.
Whole-animal approaches: mice
Although low throughput in terms of experimental numbers and
outcomes, there are several advantages to using mice as a model
organism. These include genome conservation, in which
homologues of 99% of human genes can be found in mouse
(Mouse Genome Sequencing Consortium et al., 2002), and the
availability of advanced genetic manipulation tools and complex
behavioural assays, albeit for non-human behaviours. Mouse
models have been developed for candidate schizophrenia risk loci,
such as disrupted in schizophrenia 1 (DISC1) and 22q11.2 deletion
syndrome, and for candidate autism risk loci, such as methyl CpG-
binding protein 2 (MECP2) and 15q11-13 deletion/duplication
syndromes (Amir et al., 1999; Bundey et al., 1994; Sandanam et al.,
1997). These mice exhibit behavioural deficits, as well as
neuroanatomical and neurophysiological anomalies (Robertson
and Feng, 2011). By combining cellular and whole-animal
approaches, pathological mechanisms can be revealed in human-
mouse chimeras. In this strategy, human iPSCs are introduced into
the mouse blastula, or human tissue is transplanted into older
immune-deficient mice to generate human-mouse chimeras
(Eckardt et al., 2011). Thus, the molecular identity of part of the
tissue or organ of interest is human, but functions in vivo in the
context of a whole animal. For example, grafting human glial
progenitor cells onto neonatal mice resulted in enhanced long-term
potentiation at the chimeric synapses, and enhanced learning and
memory in the mice (Han et al., 2013). On a very small scale, using a
few top candidates, mice can be used to test therapeutics. The
Mecp2mouse mutant has been used to identify a potential treatment
for Rett syndrome, involving the reversal of neurological deficits
with IGF1 (Tropea et al., 2009). IGF1 is currently being tested in
phase 2 clinical trials for Rett syndrome treatment (clinicaltrials.gov
identifier: NCT01777542).
Despite these considerable attributes, mice have multiple
limitations for use in the analysis of psychiatric disorders. Not
only are they more expensive to maintain than non-mammalian
laboratory animals, but small litter sizes render it difficult to obtain
sufficient animals for large-scale analysis. Due to this lower number
of obtained animals and the current emphasis on understanding
brain anomalies in psychiatric disorders, mice are generally not
utilized to study multiple organ systems and co-morbidities. The
expense and small numbers also affect the manner in which drugs
are tested in mice: generally pre-screening is conducted in vitro or
in silico, or hypothesis-driven candidates are chosen without any
screening (Fortney et al., 2012; Moy et al., 2014;Wang et al., 2014).
Meeting the challenges with zebrafish
We now focus on the zebrafish, an animal model that balances
experimental tractability and conservationwith humans. In addition to
being relatively cheap to raise and maintain, they also produce large
quantities of embryos. The considerable attributes of the zebrafish for
addressing psychiatric disorders include a high degree of molecular,
cellular, morphological and developmental conservation; rapid
transient genetic assays; genome-editing ability; live imaging;
characterized behaviours; co-morbidity study; and amenability to
chemical screens to define potential therapies (Box 3).
Defining genotype
Zebrafish and mammalian genomes are well conserved, with more
than 80%of human disease genes represented in the zebrafish genome
(Howe et al., 2013). Short-term molecular genetic manipulation can
be achieved by simple microinjection, using morpholino-modified
antisense oligonucleotides (MOs) (Nasevicius and Ekker, 2000) or
small interfering RNA (siRNA) (De Rienzo et al., 2012) for loss-of-
function (LOF) studies, and mRNA overexpression for gain-of-
function studies. Although MO technology is helpful, MOs might
have off-target effects, such as non-phenotypes that include activation
Box 2. Whole-animal approaches
Invertebrates:
• Challenges addressed: Genetic interactions and variant analysis,
whole-animal phenotypes for biomarkers and co-morbidity
analysis, large-scale therapeutic development.
• Pros: Whole-system/organism toxicity screen, large scale, short
time-frame.
• Cons: Less evolutionary conservation, relevance to humans might
be unclear.
Mice:
• Challenges addressed: single (or few) gene connections to
phenotype, whole-animal phenotypes for biomarkers and
co-morbidity analysis, very small-scale therapeutic development.
• Pros: Whole-animal screens, evolutionary conservation with
human genome.
• Cons: Expensive, only small-scale assays feasible, long time-
frame.
Zebrafish:
• Challenges addressed: genetic interactions and variant analysis,
whole-animal phenotypes for biomarkers and co-morbidity
analysis, mid- to large-scale therapeutic development.
• Pros: Conservation, whole-organism screens, multi-organ
analyses, medium-scale screens and short time-frame.
• Cons: Less conserved genetically and morphologically than
mammals, longer time-frame than invertebrates.
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of p53, which can be suppressed with p53 MO (Robu et al., 2007).
Stringent criteria can ensure MO phenotypes are specific: these
include preventing an MO phenotype with co-injected target RNA
(engineered to lack theMObinding site), using two differentMOs per
gene, and demonstrating changes in endogenous RNA splicing with
splice site targeting MOs (Eisen and Smith, 2008). Concerns have
been raised regarding differences between mutant and morphant
phenotypes (Kok et al., 2015); however, compensatory changes in the
transcriptome might be present in mutants but not in morphants,
perhaps contributing to the differences (Stainier et al., 2015). At
present, MO technology therefore remains useful. Human and
zebrafish gene function is often interchangeable, and introducing a
human gene (bymRNA injection or as a transgenic line) to replace the
zebrafish version to ‘humanise’ the fish is valuable for analysing the
function of human gene variants (Singh et al., 2011).
Single-gene studies can be conducted in other systems as well, so
considering the advantages of using zebrafish for genotype studies
would be prudent. One such advantage is rapid single-gene LOF
analyses of copy number variant (CNVs) genes. CNVs are
segments of the genome that have been duplicated or deleted, and
they have been significantly associated with psychiatric disorders
(Grayton et al., 2012). However, as deleterious CNVs often
encompass multiple genes, the challenge is to determine which of
these genes links the CNV to the disorder. Our group and others
have used zebrafish to investigate the 16p11.2 CNV genes, in which
deletions and duplications account for ∼0.8% of ASD cases, and
duplications account for ∼0.35% of schizophrenia cases (Malhotra
and Sebat, 2012), making this the most significant CNV for
psychiatric disorders. Different assays were chosen as a readout of
gene function, and different genes were reported as crucial: aldolase
A (aldoa) and kinesin family member 22 (kif22) for early brain
morphology, and potassium channel tetramerization domain
containing 13 (kctd13) for larval head size, implying that multiple
genes from this CNV affect several processes (Blaker-Lee et al.,
2012; Golzio et al., 2012). Another advantage of zebrafish is their
use for analysing gene-gene interactions. Rapid, MO-based, LOF
assays have highlighted many examples of zebrafish gene
interactions that inform our understanding of human disorders.
For instance, a pairwise analysis of multiple genes associated with
Bardet–Biedl syndrome – a pleiotropic intellectual disability
disorder characterized by many symptoms, including cilia
dysfunction and polydactyly – identified eight novel genetic
interactions affecting a ciliated patterning organ and fin bud
patterning/fin skeletal elements (Tayeh et al., 2008). Given the
polygenic nature of many mental health disorders, zebrafish have
great utility for the rapid study of genetic interactions.
Such gene manipulation approaches also allow for the
investigation of human gene variants, identified by sequencing
patient genomes. Determining whether these variants are causal to a
disorder is challenging, because the signal-to-noise ratio can be
quite low for common variants with low penetrance. Zebrafish
studies can complement bioinformatics predictions about function
(Samocha et al., 2014), helping to sort out which variants havewild-
type and which have abnormal activity. For example, Gauthier and
colleagues showed that a rare variant of SH3 and multiple ankyrin
repeat domains 3 (SHANK3) associated with schizophrenia could
not rescue head size and swimming deficits in a zebrafish shank3
LOF embryo, whereas a second variant and wild-type RNA could
(Gauthier et al., 2010), suggesting that the first variant was
pathological. For the schizophrenia risk locus DISC1, variants
were identified from patient pools and tested in Disc1 LOF mouse
embryos to determine which could and which could not rescue
neuronal progenitor proliferation. When they were injected in disc1
LOF zebrafish embryos, the variants that showed maintenance or
loss of activity in mice exhibited similar patterns in rescuing or not,
respectively, brain ventricle and axon tract defects in zebrafish
embryos (Singh et al., 2011). These results emphasize the
conservation of variant function between the two species, and
indicate that a much higher number of variants can be analysed in
zebrafish than is feasible in the mouse.
Targeted gene knockout and transgenic methods have also been
developed for zebrafish; thus, single or multi-genic gain- or loss-of-
function mutants can be efficiently produced to define gene
interaction networks and novel regulatory connections. Genes can
be mutated by chemical or insertional mutagenesis (Amsterdam
and Hopkins, 2006). More recently, naturally occurring pathogen
defence mechanisms in plants and bacteria have been co-opted to
develop targeted genome-editing tools for zebrafish, including
transcription activator-like effector nucleases (TALENs) and the
clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR associated protein 9 (Cas9) system, to
generate mutations in genes of interest (Hisano et al., 2013).
CRISPRs targeting five different genes have been injected into
single zebrafish embryos and induced mutations at all five loci (Jao
et al., 2013).
Finally, zebrafish are amenable to genetic tricks such as
generation of haploids, which are viable for about two days, or
gynogenetic diploids – the generation of diploid animals from only
the maternal genome – which are completely viable. This feature
makes potential screens faster and more efficient as recessive
mutations are revealed in these lines without the need for further
crossing. For example, a zebrafish genetic suppressor screen of 800
Box 3. Advantages and limitations of using zebrafish for
psychiatric disorder research
Advantages:
• Conservation of human disease genes and brain development/
anatomy.
• Rapid transient manipulations of gene expression and the rapid
development of zebrafish yields phenotypic information in days.
• Live, non-invasive time-lapse imaging provides the easiest and
best approach for studying dynamic cellular phenotypes in vivo.
• Accessibility of whole brain with the use of optogenetic tools allows
neural circuits to be identified and their function investigated.
• Psychiatrically relevant behaviours can be assayed in zebrafish,
such as sociability, anxiety, optokinetic response and conditioned
behaviour.
• The development and function of conserved organ and organ
systems can be assayed to identify co-morbidities, such as
epilepsy and digestive and immune dysfunction.
• Conservation of signalling pathways, neuronal subtypes and
neural circuits, the likely targets of drug therapies.
• High fecundity, small size, ability to be arrayed on 96-well plates
and availability of automated analysis tools make zebrafish a pre-
eminent vertebrate system for high throughput chemical screens.
Limitations:
• Caveats to transient loss-of-function analysis.
• Partial genome duplication creates potential functional redundancy
for some genes.
• Moderate length generation time.
• Trade-off in chemical screens between space for larvae and
behaviours that can be assessed.
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haploid genomes in a conditional haematopoiesis mutant identified
two suppressors (Bai et al., 2010). In summary, zebrafish genetics
are well suited for bulk transient analyses, particularly for variant
analysis and genetic interactions.
Definingmolecular phenotypes associated with psychiatric disorders
Relating genotype to psychiatrically relevant phenotypes in
laboratory animals has the caveat that human-specific behaviours
define mental health disorders. However, endophenotypes, that is,
biochemical, cell biological or molecular markers, are associated
with psychiatric disorders (Gottesman and Gould, 2003) and
might define underlying mechanism. Zebrafish are well suited
to rapidly assess a wide range of potential endophenotypes
(Norton, 2013).
With the variety of tools available for transient genetic
manipulation in rapidly developing embryos, researchers studying
zebrafish can complete phenotyping assays in just a few days. By
24 hours of age, a zebrafish embryo has formed all its major organs,
allowing many phenotypic assays to be employed. Patterns of
neurogenesis in the zebrafish CNS are generally similar to those
found in mammals (Panula et al., 2010), and the overall architecture
of the zebrafish brain closely resembles that of the mammalian
brain, although teleosts do not have a neocortex. The zebrafish
telencephalon develops by eversion rather than invagination,
resulting in somewhat different positioning of telencephalic
structures; however, the structures are conserved (Wullimann,
2009).Whereas the prefrontal cortex is known to play a considerable
role in psychiatric disorders, the cerebellum has also been strongly
implicated in their aetiology (Reeber et al., 2013). It is therefore
relevant that the anatomy and development of the human and
zebrafish cerebellum are highly conserved (Hashimoto and Hibi,
2012).
Psychiatric disorders are increasingly referred to as
‘synaptopathies’ because of the presence of drug targets, risk-
gene candidates and aberrant signalling at the synapse (Grant,
2012). Due to the plasticity of synapse generation and function,
more can be learned from observing synapses in intact circuits
in vivo than from fixed, post-mortem samples. The transparency of
the zebrafish embryo supports live imaging at single-cell resolution
to develop cellular assays of neuropathology. For example, using
fluorescent labels, time-lapse microscopy has enabled researchers to
examine dendritic arborisation in vivo. This included evaluating the
changing dynamics for pre-synaptic activity, competition from
neighbours affecting outgrowth and the turnover of synapses in
zebrafish (Ben Fredj et al., 2010; Meyer and Smith, 2006). These
assays offer unprecedented neural function analysis in the living
animal.
Integral to understanding the pathology that underlies psychiatric
disorders is the characterization of neuronal circuits. The zebrafish is
well suited for this, as transgenic lines are straightforward to create,
and hundreds of GAL4 enhancer trap lines have been generated with
varying neural expression patterns. In this approach, the gene
encoding the yeast transcription activator protein GAL4 is expressed
in only a subset of neuronal cells. These GAL4 lines are then
crossed with zebrafish transgenic lines harbouring fluorescent
reporter genes downstream of an upstream activating sequence
(UAS) to which GAL4 specifically binds; this will drive the
expression of the fluorescent reporter and thus make this subset of
neuronal cells visible (Asakawa and Kawakami, 2008; Scott et al.,
2007). Because of its external fertilization, transparency and small
brain size, the larval zebrafish brain is nearly entirely accessible to
two-photon stimulation and to activity readouts without any
invasive surgery. Optogenetic tools for manipulating neuronal
activity and fluorescent indicators of calcium activity (such as
GCamP) have been used to dissect circuit components for
behaviours in zebrafish (Fajardo et al., 2013; Kimura et al., 2013;
Wyart et al., 2009). These approaches have revealed that the
saccade-generating neurons of the optokinetic response (which is
when the eyes track a moving object until it exits in the field of view
and then reset to where the movement entered the field of view), a
behaviour that is defective in several psychiatric disorders, are
located in a small area of the zebrafish hindbrain in rhombomere 5
(Schoonheim et al., 2010).
Linking molecular pathology to behaviour might be the most
challenging step in understanding psychiatric disorders. Whereas
zebrafish do not generally phenocopy human behaviour, they do
exhibit a repertoire of stereotypic behaviours with potential
psychiatric relevance that could be useful indicators of gene
function (Brennan, 2011; Stewart et al., 2013). These behaviours
include sociability, anxiety, the optokinetic response and
conditioned behaviour. Social aberrations are a defining
symptom of ASDs but can also be noted in schizophrenia and
mood disorders. Zebrafish are a good system to examine sociability
because they spend 90% of their time in a shoal or in loose
groupings (Buske and Gerlai, 2012). When zebrafish are treated
with MK-801, a compound used to induce autistic and
schizophrenic behaviours in rodents (Neill et al., 2010), they
exhibit disrupted shoaling behaviours (Maaswinkel et al., 2013).
Anxiety is a co-morbidity for psychiatric disorders; nearly 30% of
Americans will suffer from some anxiety disorder in their lifetimes
(Kessler et al., 2005a). Defects in glucocorticoid signalling are
associated with depression and psychosis (Pariante, 2009).
Similarly, a zebrafish glucocorticoid receptor mutant shows
increased anxiety in the novel tank diving assay: these fish freeze
and show reduced exploratory behaviour, which can be rescued
with the addition of antidepressants to their holding water (Ziv
et al., 2013). Furthermore, optokinetic response deficits are
associated with several psychiatric disorders (Bittencourt et al.,
2013; Trillenberg et al., 2004). SNPs near the dopa decarboxylase
gene (DDC) have been significantly associated with autism (Toma
et al., 2013), and ddc knockdown in zebrafish results in a defective
optokinetic response (Shih et al., 2013). Finally, assaying
conditioned behaviour in zebrafish can probe aberrations in
cognitive function, learning deficits and memory, all of which
have been tied to psychiatric disorders. After being conditioned
with shock stimuli, zebrafish mutant for the fragile-X-associated
gene fmr1 show decreased latency to enter the shock zone of their
tanks compared with wild-type fish, implying that they have a
deficit in inhibitory avoidance learning (Ng et al., 2013).
Also integral to defining pathology is identifying the co-
morbidities associated with particular psychiatric disorders.
Zebrafish exhibit similar physiology to humans in digestive and
immune function (Renshaw and Trede, 2012; Shepherd and Eisen,
2011), both of which can be compromised in psychiatric patients
(Hamdani et al., 2013; McElhanon et al., 2014). Intestinal function
can be monitored in zebrafish by utilizing microgavage and
fluorescent beads or by liposome incubation (Carten et al., 2011;
Cocchiaro and Rawls, 2013). Seizure behaviours, which are also
often associated with psychiatric disorders, have been studied
extensively in zebrafish as well (Baraban et al., 2005; Stewart et al.,
2012). The transparency of these fish, the availability of transgenic
reporter lines and behavioural analyses, and live assays of conserved
neural circuit and organ function afford unique opportunities to
study such phenotypes in zebrafish.
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Defining new therapies for psychiatric disorders using
zebrafish
All known mammalian signalling pathways are conserved in
zebrafish, and almost all are active in the zebrafish embryo as the
brain and other organs begin to develop (Stuhlmiller and García-
Castro, 2012; Wullimann, 2009). As many such pathways are likely
to be implicated in psychiatric disorders and can be targeted by
potential therapeutics, the zebrafish embryo and larva can act as a
whole-animal test tube for chemical screens. For small molecule
screens, the small size of zebrafish embryos and larvae, and the
large numbers that can be obtained, make the zebrafish the most
powerful whole-vertebrate tool. The system is also useful for
monitoring the toxicity and side effects of drugs at the organismal
level.
Chemical screens relevant to psychiatric disorders have been
conducted in zebrafish. As aberrations in Wnt signalling and
glucocorticoid signalling have been implicated in mental health
disorders (Freyberg et al., 2010; Pariante, 2009; Voleti and Duman,
2012), zebrafish chemical screens have been conducted for
modulators of β-catenin (Hao et al., 2013) and glucocorticoid
signalling (Weger et al., 2012). In addition, screens for compounds
that affect sleep have been carried out (Rihel et al., 2010), as circadian/
sleep disturbances are often associated with psychiatric disorders
(Dueck et al., 2012). Finally, by combining known and unknown
psychotropic chemical libraries and using a behavioural readout,
researchers used zebrafish to uncover novel classes of neuroactive
compounds and predict their targets (Kokel et al., 2010).
Several zebrafish chemical screens have contributed to
developing drugs that are currently in clinical trials. A compound
that improves engraftment in umbilical cord hematopoietic stem cell
transplants is currently undergoing clinical trial (Cutler et al., 2013;
Goessling et al., 2011), as are a drug to kill melanoma cells (White
et al., 2011) and a compound to treat Duchenne muscular dystrophy
(Kawahara et al., 2011; Martin et al., 2012). Together, these
examples indicate that chemical screens in zebrafish can produce
effective and translatable results in the development of treatments
for psychiatric disorders.
Concluding perspectives
How does this rich landscape of methodological possibilities
integrate with psychiatric disorder diagnosis for a patient? We
explore this in Fig. 2. After receiving a diagnosis from the physician,
a patient will often want to try the available treatments. But patient
and physician can also connect with a human geneticist to have the
patient and unaffected family member DNA sequenced to identify
putative, contributing risk genes. Depending on the candidate risk
genes identified, different tools will give different deliverables in
different time frames. These tools complement one another in terms
of readouts and scale of chemical screens. Putting these approaches
together maximizes the chance of effectively identifying causal
genotype, diagnostics and therapeutics.
There are things a zebrafish cannot do. A zebrafish cannot show
human autism or schizophrenia behaviours. But neither can a
mouse. Some genes are not conserved and the zebrafish brain has
only rudimentary cerebral hemispheres. All animal models have
their limitations and must continually be evaluated as to whether
they display phenotypes relevant to a psychiatric disorder. As we
have explored, to define the molecular basis for each psychiatric
disease, a substantial set of animal model and cell-based tools will
be needed, and among these, the zebrafish is an effective and useful
contributor.
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